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Abstract
Persistent infection with high-risk Human papillomavirus (hr-HPV 16, 18, 31, 33, and 45) is the main risk factor for developing 
malignant genital lesions. Screening methods and follow-up schedules for cervical cancer are well known. A golden standard 
to screen and monitor men does not exist yet, because HPV-related, life threatening malignancies in men are rare. The 
importance of male HPV screening lies mainly in HPV vaccination. Young females are the target group for HPV, but men 
are considered to be the reservoir for HPV and to have a role in the perpetuation of the infection in the general population.
We looked at the usefulness of urine as a tool for HPV screening. Pubmed was searched with the words HPV, Urine, 
and HPV-DNA. The chance of Þ nding HPV-DNA in urine is higher in men with lesions in the urethra than outside the 
urethra, and in women with abnormal cervical cytology. In general, the results of testing urine for HPV-DNA are better for 
women than for men, probably because of the anatomical position of the urethra to the vagina, vulva, and cervix. In both 
genders, urine HPV prevalence is higher in HIVpos patients and in high-risk populations. Urine, to screen asymptomatic 
low-risk-proÞ le (wo)men seems less useful because their urine samples are often inadequate. If urine proves to be the 
best medium to screen, a low-risk population remains controversial.
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Human papillomavirus (HPV) infection is a sexually 
transmitted infection (STI). Low-risk HPV (lr-HPV) 
6 and 11 are responsible for genital warts. Persistent 
infection with high-risk HPV (hr-HPV 16, 18, 31, 33, 
and 45) is the main risk factor for developing genital 
(pre) malignant lesions.[1] Co-risk factors are sex at an 
early age, promiscuity, alcohol and drug abuse, and 
lack of condom use.[2] In women HPV-DNA-PCR 
on cervical scrapes is used to identify the HPV-type 
responsible for the detected lesions. The golden standard 
to screen men is still under research. 
HPV Screening
Persistent infection with hr-HPV is the main risk 
factor for developing cervical, penile, and anal cancer. 
Cervical cancer is the second most common cancer in 
women worldwide and a significant cause of death. 
Cervical scrapes for HPV-DNA-PCR are more sensitive 
than cytology and have become the golden standard 
for primary screening and follow up of women. 
Standardized screening of men has not been fully 
elaborated yet, because HPV-related, life-threatening 
malignancies in men are rare. However, literature about 
the best way to diagnose HPV in asymptomatic men is 
growing. Of late a combination of samples of the penile 
shaft and the glans penis/coronal sulcus, combined with 
a scrotal, perianal or anal sample was proposed.[3]
This review looks at the usefulness of urine as a 
screening tool for HPV in both sexes. Urine would 
be an ideal sample for screening large populations 
and children, as well as for monitoring adolescents 
and adults. A urine test may increase participation 
and compliance, since physical scrapes, sometimes 
unpopular because of the dislike of physical examination 
or because of religious reasons, are avoided. Reliable 
screening kits using PCR-testing on the first voided 
urine (FVU) are available for other STIs, for example, 
Chlamydia trachomatis.[4] HPV-DNA in FVU represents 
infected cells shed from the epithelium of the urethra/
urethral meatus and from the cervix and vagina in 
women. The β-Globin concentration in a sample is 
the internal test for the amount of shed cells and for 
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the DNA quality. However, 6% of male samples were 
found to be positive for HPV-DNA, although negative 
for β-Globin.[5] Efforts have been made to detect the 
presence of HPV-DNA in urine in the most reliable 
way, using liquid hybridization, conventional PCR, 
and real-time, PCR-based methods. Optimization 
of the technique was described in 2004.[6] Different 
factors with a possible influence on the results were 
examined. The authors concluded that the presence 
of proteins in urine ameliorates amplification, while 
nitrites decrease amplification. Adding a dilution 
step and a concentration step before applying the 
Qiagen protocol increased the amplification of β-Globin 
(from 50 to 63%) and of the HPV L1 gene (from 
13 to 33%). Refrigerating the specimens at four 
degrees Celsius overnight produced better amplification, 
versus immediate processing or versus freezing the 
specimen for 24 hours. Another two groups published 
good results with PCR and real-time-PCR (RT-PCR). 
Daponte examined 100 consecutive women referred to 
the colposcopy clinic with abnormal cervical cytology 
and normal urine parameters.[7] Paired urine and 
cervical specimens were submitted for an in-house PCR 
method (HPV type 16 and 18) and a multiplex PCR 
method (HPV type 6, 11, 16, 18 and 33). He found 
a urine/cervix HPV detection sensitivity of 76.5% in 
cases with high-grade lesions and of 45.5% in cases 
with low-grade lesions. In all concordant cases the 
same HPV type was detected in both samples. The 
sensitivity enhanced when there were two or more 
epithelial cells per field, in urine microscopy. Two years 
later he confirmed his results by submitting the urine 
of another 100 cervical HPV-16-positive women to 
RT-PCR.[8] Urine sensitivities for cancer, high grade 
lesions, and low grade lesions were, 93.3, 83.3, and 
38.8%, respectively, with RT-PCR vs. 86.7, 72.2, and 
32.7% with conventional PCR. The mean viral load in 
urine was significantly lower than in the cervical swab. 
Payan had similar results using RT-PCR on cervical 
(n = 333) and urine (n = 177) samples of women 
referred for gynaecological examination and PAP-smear. [9] 
Respectively, 45 and 37% of the samples were HPV 
positive: the latter with a significant 50-fold-lower mean 
viral load.
When using urine for HPV-screening in asymptomatic 
women, the results vary depending on the chosen 
population. In a population of sexually unexposed 
college girls only six out of 100 urine samples tested 
positive.[10] In the USA 3262 sexually active women, 
aged 18 to 25 years, were included in the WAVE III 
Study (National Longitudinal Study of Adolescent 
Health), and each produced a urine sample.[2] Overall, 
HPV prevalence was 26.9%, and 14.3% in women 
with one lifetime partner. High-risk types were detected 
in 20%, of which 10% were infected with types 
covered by the current vaccines. Jacobson found any 
HPV in 90% of cervical scrapes and in 75% of urine 
samples in a group of 80 sexually active Afro-American 
adolescents. [11] These last two studies show that urine 
may be a good tool to screen a mass population.
Overall, the results of detecting HPV-DNA in FVU 
are better in women than in men, probably because of 
the anatomical position of the urethra to the vagina, 
vulva, and cervix. Sellors described that the concordance 
between cervical specimens and the vaginal, vulvar, and 
urine specimens for the presence of HPV was 0.76, 
0.55, and 0.41, respectively. [12] 
Human papillomavirus prevalence increases when 
abnormal cervical cytology and/or HIV-positivity 
is involved. Forslund found that 65% of the urine 
samples of women with HPVpos cervical scrapes were 
HPV-positive, while 85% of the patients with HPV-
DNApos urine also had HPV-DNA in their cervical 
scrapes.[13] Vossler found additional value in urine 
testing in women with cervical dysplasia.[14] The same 
good results were observed in Korea when urine and 
cervical swabs of women with cervical lesions were 
matched: HPV-DNA was found in 70 / 100 cervical 
samples and in 47 / 90 urine samples.[15 ] Type-specific 
agreements were good for HPV 16, 18, 52, and 58. 
Similar results were seen in Greece,[7] in patients with 
HPV-16-infection, and in Zimbabwe,[16] in women who 
had invasive cervical cancer. Fambrini successfully used 
urine for the follow up of women after conization of 
their cervical lesions; this resulted in 96.6% concordance 
between cervical scrapes and urine.[17] Powell found that 
young girls (children) with Lichen Sclerosus (LS) and 
non-LS-related vulvar pathology had a higher chance 
of intermediate and high-risk-HPV than girls with no 
known vulvar disease.[18] Recent studies showed HPV 
prevalence in HIVpos-womens urine and cervical smear 
samples, of 48-81.5 and 51.9-58%, respectively.[19,20] 
Concordance between the samples was 71% in both 
studies. 
These days highly effective vaccines for HPV type 6, 
11, 16, and 18 are available, covering about 70% of the 
cervical cancers. By partial cross-protection against HPV 
31 and 45, this could rise to 76%.[21] The vaccines 
are most preventive when given before the first sexual 
encounter (age < 11 years). Although young females 
are the main target group for this vaccination, one 
could consider vaccinating men as well. A counter-
argument is that men already profit from herd immunity 
when all young women are vaccinated. An argument 
pro male vaccination is aiming to protect all sexually 
active people. If an individual is infected with one HPV 
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type, vaccination will protect him against the other three 
types. The present vaccines protect men also from HPV 
types 6 and 11. We expect that the same will happen 
for HPV types 16 and 18, but this is still hypothetical. 
Furthermore, recent data indicate that males experience 
a longer duration of genital warts than women, which 
leads to greater treatment costs. Widespread use of 
HPV-vaccines can reduce the workload at STI clinics by 
approximately 10%, without a substantial impact on the 
diagnosis and treatment of other STIs.[22] However, at 
present there is no treatment for asymptomatic high-risk 
men. A screening test capable of detecting subclinical 
HPV infections in males would be of value, should 
effective therapy be discovered.
In general, urine samples to detect HPV in 
asymptomatic men are less useful. Hillman conducted 
several studies on HPV-DNA in urine of men. He 
examined men with penile warts, genital gonorrhoea, 
and genital dermatoses: few positive samples were 
found. There was no relation between visual lesions 
and HPV positivity.[ 23-25] Geddy tested urine sediments 
of 73 men attending the STI clinic; among them were 
14 patients with genital warts that did not involve the 
urethral meatus.[26] He did not find HPV-DNA in any 
of the specimens, while human  β-Globin was identified 
in 40 out of the 73 samples. He concluded that urine 
is unhelpful for studying the prevalence of urethral 
HPV infection in men. Fife examined men visiting the 
STI polyclinic and found a low sensitivity for HPV in 
urine, mainly because of the inadequacy of the sample 
material.[27] Melchers on the other hand detected HPV-
DNA in 15 out of 17 male patients with condylomata 
accuminata in the urethral meatus.[28] Iwasawa examined 
the urine of 29 patients with urethral condylomata, 
three patients with penile condylomata, and 15 control 
patients.[29] HPV-DNA was found in 76, 0, and 0%, 
respectively. He found additional value in testing the 
urine for HPV screening of the male genital tract. 
Smits compared the urine of 114 HIVpos-men and 
115 HIVneg-men.[30] The prevalence of HPV in HIVpos 
patients was 39.4%, being 81.4% high-risk type. In the 
HIV uninfected men 9.6% of the samples tested HPV 
positive. 
Urine sampling for detection of HPV in women 
and their male partners is controversial. Nakazawa 
detected HPV-DNA in 2 / 8 urine samples of male 
partners whose wives were HPV positive.[31] A few 
years later Astori collected urine and urethral swabs 
of 70 asymptomatic male partners of HPV-DNA 
positive women.[32] He used the Dot blot Technique 
as well as PCR. PCR gave better results than the Dot 
blot; nevertheless 87% of the urethral swabs were 
inadequate and 21% of the urine was inadequate. In 
Argentina, urine of men presenting with penile lesions 
and of men with HPV positive partners was examined 
with nested PCR.[33] Urine tested positive in 79.5 
and 68.8%, respectively. Eleven percent had a double 
infection. In India cervical scrapes and urine of 30 
healthy women and of 30 women with cervical cancer 
were compared with their husbands penile scrapes 
and urine.[34]  All groups showed a similar frequency of 
HPV infection both in urine and scrape samples, but 
there was a significant difference in the prevalence of 
high-risk type 16 in women with cervical cancer and 
their male partners. Our own study, where we tested 
31 FVU of healthy females and 30 FVU of healthy 
men, showed 71 and 66.7% adequacy, respectively. [35]  
HPV-DNA was found in 3.2% of female FVU. Our 
second study (unpublished observations), which included 
asymptomatic men, showed 20% adequacy, so we 
stopped urine testing - supported by the article of 
Giuliano.[3] 
Conclusion
Urine is an easy, self-obtainable sample, which could 
be ideal to screen for HPV, if reliable. Earlier articles 
mention a varying prevalence of HPV in urine, 
depending of the screening population. Recent articles 
find a high prevalence of HPV, but mainly in high-risk 
populations. Urine will probably become a diagnostic 
tool for follow up of women treated for (cervical intra-
epithelial neoplasia) CIN / HSIL (high-grade squamous 
intra-epithelial lesions), for HIVpos women, and for 
detecting the HPV-type in a high-risk (a)symptomatic 
male population; for example, partners of women with 
HR-HPV related lesions, male prostitutes, HIVpos men, 
men repeatedly having unprotected sex with different 
(wo)men. Urine can be kept in mind for screening of 
mass population. Whether urine is the best medium 
for specific screening of asymptomatic low-risk men is 
questionable.
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